Xeris Biopharma Holdings (XERS) Cash from Operations (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Cash from Operations for 7 consecutive years, with $8.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 4440.11% year-over-year to $8.3 million; the trailing twelve-month figure through Jun 2026 stood at $56.6 million (up 449.89% YoY), and the FY2025 full-year result was $28.6 million, up 177.41% from the prior year.
• Cash from Operations retreated to $8.3 million in Q2 2026 per XERS's latest filing, from $9.9 million in the prior quarter.
• Across five years, Cash from Operations topped out at $20.0 million in Q4 2025 and bottomed at -$48.4 million in Q1 2022.
• Historically, Cash from Operations has averaged -$7.8 million across 5 years, with a median of -$10.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Cash from Operations plunged 102.07% in 2022, then soared 4440.11% in 2026.
• Over 5 years, Cash from Operations stood at -$16.1 million in 2022, then soared by 146.35% to $7.5 million in 2023, then plunged by 73.56% to $2.0 million in 2024, then surged by 914.84% to $20.0 million in 2025, then tumbled by 58.77% to $8.3 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $8.3 million, $9.9 million, and $20.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.